Navigation Links
How a cancer drug leads to diabetes
Date:4/3/2012

The drug known as rapamycin is widely used by cancer and transplant patients, and there are hints that it might even help us put off old age and live longer. But, it also comes with a downside: rapamycin leads to diabetes in as many as 15 percent of the people who take it.

Now, researchers reporting in the April Cell Metabolism, a Cell Press publication, have figured out why that is. The drug turns the insulin signal off in muscle, to prevent muscle cells from taking blood sugar in.

"This is a drug that is pretty well known for its benefits," said Pere Puigserver of Dana-Farber Cancer Institute. "Rapamycin is one of the few drugs, maybe the only one, that extends lifespan in organisms from yeast to mice to primates."

But the drug's diabetic side effects are troubling, and Puigserver's team now finds they arise in an interesting way. The key is a single transcription factor in muscle known as YY1. Mice lacking YY1 are protected from diabetes when they take rapamycin.

That's because rapamycin changes YY1 within muscle and that shift leads to chemical and structural modifications of the genes encoding insulin signals. Those changes effectively turn insulin off, keeping sugar from coming in.

That rapamycin leads to long life even as it causes insulin resistance remains something of a paradox, Puigserver says. His team does have hints that there may be other factors at play. For instance, he says diet might make the difference between those who develop diabetes while on rapamycin and those who do not.

The results also have fundamental interest as perhaps the first instance in which the nutrient signal mTOR -- the target of rapamycin -- has been tied to epigenetic changes in the genome. (Epigenetic changes are defined as chemical modifications to DNA that can take place without any change in the underlying sequence of As, Gs, Ts and Cs.) The finding may reveal a more general mechanism by which other nutrient changes could act via mTOR to control the epigenetic state of genes, with impacts in metabolism and diseases.

On the practical side, the findings support the notion that at least some people taking rapamycin should also take anti-diabetic drugs, Puigserver says. These side effects will also need to be factored into any cost-benefit analysis of further uses of the drug, the researchers say, including for any future use in lifespan extension.


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Enhancing arrest of cell growth to treat cancer in mice
2. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
3. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
4. Low forms of cyclin E reduce breast cancer drugs effectiveness
5. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
6. Soft drinks may increase risk of pancreatic cancer
7. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
8. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
9. Single gene mutation induces endometrial cancer
10. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
11. Molecular pathways linked to sex, age affect outcomes in lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... newly redesigned website, federallabs.org . The site houses a wealth of federal ... federal technologies through the process called technology transfer (T2). As a network of ...
(Date:2/8/2016)... ... , ... The Valentine’s Season is famous for gift giving with flowers, chocolates and other tokens ... This year, for more than 5.6 million Americans suffering with Alzheimer’s, those store bought ... remind them of the lives they’ve led and the people they’ve touched. , ...
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley Rubber Corporation ... to provide its range of unique and advantaged protective solutions to a ... will provide bilingual customer service and marketing support. A new distribution center in ...
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and its affiliated companies ... Gary D. Radine, who recently retired as president and CEO of Delta Dental of ... CEO of the Year , helped lead the effort to raise funds for studies ...
(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's document management software ... provides a cloud hosted environment for FileHold software that is pay per user ... party applications using the FileHold web services API. DocuSyst also advises clients on ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016 In a historic vote among its ... to construct a medical cannabis cultivation facility and dispensary on tribal land ... New York as a provider for patients in the state,s ... as a provider for patients in the state,s Medical Cannabis ... (34) to approve the project and pursue designation from the ...
(Date:2/8/2016)...   Intarcia Therapeutics, Inc. today announced the ... the newly created role of Vice President, Head of ... two decades of leadership experience at leading pharmaceutical, biotechnology, ... medical center. Most recently Dr. Yee served as VP, ... Head Medical Officer at AstraZeneca, where he led medical ...
(Date:2/8/2016)... PAOLI, Pa. , Feb. 8, 2016  As part ... Ltd has announced today the appointment of Lori Chmura ... more than 20 years in the industry, Chmura,s extensive experience ... in the advancement of Dune Medical Devices. ... Lori will be responsible for leading all sales, marketing and ...
Breaking Medicine Technology: